CATALYST PHARMACEUTICALS INC's ticker is CPRX and the CUSIP is 14888U101. A total of 259 filers reported holding CATALYST PHARMACEUTICALS INC in Q4 2023. The put-call ratio across all filers is 0.58 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $2,376 | -2.8% | 153,391 | 0.0% | 5.62% | -6.6% |
Q1 2024 | $2,445 | -5.8% | 153,391 | -0.7% | 6.02% | -5.2% |
Q4 2023 | $2,596 | +39.0% | 154,431 | -3.4% | 6.35% | +19.0% |
Q3 2023 | $1,868 | -13.0% | 159,791 | 0.0% | 5.34% | -8.1% |
Q2 2023 | $2,148 | -12.6% | 159,791 | +7.8% | 5.81% | -18.6% |
Q1 2023 | $2,458 | -10.9% | 148,281 | 0.0% | 7.14% | -18.4% |
Q4 2022 | $2,758 | -99.9% | 148,281 | 0.0% | 8.75% | +54.2% |
Q3 2022 | $1,902,000 | +37.5% | 148,281 | -24.8% | 5.68% | +26.2% |
Q2 2022 | $1,383,000 | -19.9% | 197,251 | -5.3% | 4.50% | +29.0% |
Q1 2022 | $1,726,000 | +19.4% | 208,189 | -2.5% | 3.48% | +26.8% |
Q4 2021 | $1,446,000 | +34.4% | 213,609 | +5.2% | 2.75% | +79.0% |
Q3 2021 | $1,076,000 | +8.1% | 203,079 | +17.3% | 1.54% | +14.2% |
Q2 2021 | $995,000 | -4.0% | 173,079 | -23.0% | 1.34% | +2.3% |
Q1 2021 | $1,036,000 | +37.8% | 224,774 | -0.2% | 1.31% | -21.3% |
Q4 2020 | $752,000 | +0.4% | 225,274 | -10.7% | 1.67% | -28.8% |
Q3 2020 | $749,000 | -42.8% | 252,199 | -11.0% | 2.35% | -42.2% |
Q2 2020 | $1,310,000 | +22.5% | 283,494 | +2.1% | 4.06% | -13.2% |
Q1 2020 | $1,069,000 | +0.9% | 277,774 | -1.6% | 4.68% | +39.4% |
Q4 2019 | $1,059,000 | -29.6% | 282,424 | -0.3% | 3.36% | -30.9% |
Q3 2019 | $1,505,000 | +73.8% | 283,334 | +25.6% | 4.86% | +83.2% |
Q2 2019 | $866,000 | -27.3% | 225,584 | -3.5% | 2.65% | -26.2% |
Q1 2019 | $1,192,000 | +147.8% | 233,794 | -6.7% | 3.59% | +135.1% |
Q4 2018 | $481,000 | -49.3% | 250,683 | 0.0% | 1.53% | -30.6% |
Q3 2018 | $948,000 | +21.2% | 250,683 | 0.0% | 2.20% | +17.5% |
Q2 2018 | $782,000 | +27.6% | 250,683 | -2.3% | 1.88% | +28.0% |
Q1 2018 | $613,000 | -38.9% | 256,593 | 0.0% | 1.46% | -36.0% |
Q4 2017 | $1,003,000 | +65.0% | 256,593 | +6.4% | 2.29% | +68.9% |
Q3 2017 | $608,000 | -8.6% | 241,078 | 0.0% | 1.36% | -11.0% |
Q2 2017 | $665,000 | +59.9% | 241,078 | -0.3% | 1.52% | +66.2% |
Q1 2017 | $416,000 | -29.5% | 241,753 | -59.0% | 0.92% | -33.6% |
Q4 2016 | $590,000 | -17.1% | 589,883 | -13.5% | 1.38% | -19.1% |
Q3 2016 | $712,000 | +53.4% | 681,613 | 0.0% | 1.71% | +43.2% |
Q2 2016 | $464,000 | -39.3% | 681,613 | 0.0% | 1.19% | -30.7% |
Q1 2016 | $764,000 | +222.4% | 681,613 | +510.3% | 1.72% | +237.1% |
Q4 2015 | $237,000 | -29.3% | 111,693 | 0.0% | 0.51% | -39.8% |
Q3 2015 | $335,000 | -27.5% | 111,693 | 0.0% | 0.85% | -26.1% |
Q2 2015 | $462,000 | +5.5% | 111,693 | 0.0% | 1.15% | -5.4% |
Q1 2015 | $438,000 | +23.4% | 111,693 | -19.4% | 1.21% | +14.7% |
Q4 2014 | $355,000 | -14.3% | 138,493 | -6.4% | 1.06% | -12.5% |
Q3 2014 | $414,000 | -29.7% | 147,993 | -50.0% | 1.21% | +47.2% |
Q2 2014 | $589,000 | +97.7% | 295,986 | +100.0% | 0.82% | -9.4% |
Q1 2014 | $298,000 | +18.7% | 147,993 | 0.0% | 0.90% | +22.5% |
Q4 2013 | $251,000 | -39.4% | 147,993 | 0.0% | 0.74% | -48.1% |
Q3 2013 | $414,000 | +286.9% | 147,993 | 0.0% | 1.42% | +273.0% |
Q2 2013 | $107,000 | – | 147,993 | – | 0.38% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Consonance Capital Management LP | 17,875,655 | $94,920,000 | 9.39% |
TANAKA CAPITAL MANAGEMENT INC | 283,334 | $1,505,000 | 4.86% |
GABLES CAPITAL MANAGEMENT INC. | 490,564 | $2,606,000 | 1.84% |
MANGROVE PARTNERS IM, LLC | 2,508,838 | $13,322,000 | 1.61% |
Broadfin Capital, LLC | 880,303 | $4,674,000 | 0.86% |
Atom Investors LP | 1,012,355 | $5,376,000 | 0.37% |
Capital Impact Advisors, LLC | 179,868 | $948,000 | 0.36% |
KNOTT DAVID M | 151,415 | $804,000 | 0.34% |
EMERALD ADVISERS, LLC | 1,175,958 | $6,244,000 | 0.29% |
CADENCE CAPITAL MANAGEMENT LLC | 371,075 | $1,970,000 | 0.28% |